Loading…
← CockpitCompetitor Analysis › SENORES.NS Senores Pharmaceuticals Ltd.Open in the cockpit ↗

Senores Pharmaceuticals Ltd.SENORES.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum laggard 14
Mkt cap
$538M
US dollars, full cap
Free float
46%
of shares outstanding
$/day
$4.76M
20-day average traded
Fwd P/E
32.2×
forward earnings
ROIC−WACC
-0.2 pp
WACC 9.7%
Hurdle
n/a
no reverse DCF
Next earnings
71 days
28 Jan 2027
Close · INR₹1,093
1D-4.0%
1W-6.9%
1M-12.8%
3M-28.9%
6M+3.4%
YTD+32.9%
1Y+40.7%
ATR %5.2%
Beta0.85
52w lowhigh31.7% off high

What Senores Pharmaceuticals does

Employees: 368

Senores Pharmaceuticals at a glance

Size Senores Pharmaceuticals (SENORES.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $538M, the 824th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,093 on 18 Nov 2026.

Performance Over six months the shares gained 3.4%, against -16.7% for the median peer and +3.8% for the India market (cap-weighted) — 5th highest of 19 in its peer set.

Growth Revenue grew 39.7% over the last twelve months (peer median -1.0%); the operating margin is 24.3% (peer median 6.3%).

Valuation It trades at 32.2× forward earnings against a peer median of 11.3× (2nd most expensive of 9).

Capital Return on invested capital runs 0.2 points below its cost of capital (9.7% WACC).

Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026SENORES.NS 101Peer median 84
Six months, rebased to 100: Senores Pharmaceuticals against the median of its 20 peers (local-currency closes).

Senores Pharmaceuticals financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹7.22B₹6.33B₹3.97B₹2.14B₹353M
Revenue growth—+59%+86%+506%—
Gross profit₹2.96B₹2.07B₹1.21B₹541M₹160M
EBITDA₹2.13B₹1.68B₹888M₹411M₹127M
Net income₹1.33B₹1.15B₹586M₹315M₹84.3M
Free cash flown/a-₹2.13B-₹2.17B-₹856M-₹502M
Capital expendituren/a₹2.65B₹1.58B₹518M₹473M
Total debt₹4.17B₹3.42B₹3.15B₹2.58B₹626M

Quarterly statements and history in the cockpit →

Senores Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-20%0%+20%MOREPENLAB603222000919SUPRIYA0026884559ZVRA688356ENTXALMSEGTXINDPSENORES.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Senores Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%+80%10×20×30×SUPRIYA0026884559ZVRA003850002393688356EGTXSENORES.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Senores Pharmaceuticals is the large dot.

Senores Pharmaceuticals competitors and peer comparison

How Senores Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Senores Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureSENORES.NSPeer medianRank in peer set
1-month return-12.8%-7.2%6th lowest of 20
6-month return+3.4%-16.7%5th highest of 19
Distance from 52-week high-31.7%-40.7%5th highest of 20
Revenue growth (TTM)+39.7%-1.0%3rd highest of 19
Operating margin24.3%6.3%3rd highest of 18
Forward P/E32.2×11.3×2nd most expensive of 9
ROIC minus cost of capital-0.2 pp-3.4 pp6th highest of 16
EV / EBITDA25.3×7.9×most expensive of 6
Net debt / EBITDA1.5×0.3×3rd most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Senores Pharmaceuticals SENORES.NSIndia$538M+3%+40%24%32.2×n/an/a
Morepen Laboratories MOREPENLAB.NSIndia$542M+121%+30%11%n/an/an/a
Chimin Health Management 603222.SSChina$533M-31%+1%-28%n/an/an/a
Electra Therapeutics ETRAUnited States$530Mn/an/an/an/an/an/a
Jinling Pharmaceutical 000919.SZChina$529M-15%-8%1%n/a2.4%+5.0%
Supriya Lifescience SUPRIYA.NSIndia$529M-15%+23%26%36.2×28.2%+15.8%
Evonile Pharma EVONILE.NSIndia$529Mn/a-5%12%n/a49.3%-1.5%
Jinhe Biotechnology 002688.SZChina$550M-19%+7%5%8.9×1.0%+9.7%
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%9.6×-12.3%+11.1%
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%11.3×-4.9%+51.6%
Boryung 003850.KSSouth Korea$554M-13%+6%6%11.3×-3.1%+12.6%
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%n/an/an/a
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%9.0×-5.8%+4.1%
Beijing Science Sun Pharmaceutical 300485.SZChina$517M-29%-11%-8%n/an/an/a
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%n/an/an/a
Jenkem Technology 688356.SSChina$563M-30%+52%11%30.2×36.4%+11.2%
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%n/a-6.1%+9.6%
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Alumis ALMSUnited States$569M-80%-67%-5,375%n/an/an/a
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%15.1×n/an/a
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a

Questions

Which companies are Senores Pharmaceuticals's closest peers?
The cockpit's peer set: Morepen Laboratories (MOREPENLAB.NS), Chimin Health Management (603222.SS), Electra Therapeutics (ETRA), Jinling Pharmaceutical (000919.SZ), Supriya Lifescience (SUPRIYA.NS), Evonile Pharma (EVONILE.NS), Jinhe Biotechnology (002688.SZ), Zeria Pharmaceutical (4559.T).
Is Senores Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 32.2× against a peer median of 11.3×, 2nd most expensive of 9 in its peer set.
How has Senores Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +3.4% against -16.7% for the median peer; over one year +40.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.